EGFR and neoplasm: Indeed, using MIA PaCa-2 cells as an in vitro PDAC model, the authors demonstrated that cetuximab-conjugated TPMIL increased up to 34-folds of the specificity of liposome binding to EGFR-overexpressing cells with respect to the untargeted counterpart (PMIL), thus confirming the tumor specificity of the targeted nanoconstruct as well as the exceptional photo-toxic effect determined after a 690 nm light cells activation (IC50 measured for TPMIL decreased by 21-folds with respect to that for untargeted PMIL).